Active Clinical Trials

Active Clinical Trials at Huron Gastro are listed below. If you have any questions about our current research, please contact our research department at research@hurongastro.com or call 734.714.0523  

Active Clinical Trials

 

  • A Phase 2b/3, Multicentered, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (M14-234 I/M)
     
  • A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in subjects with Ulcerative Colitis (AbbVie M14-533)
     
  • A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn's Disease (Lilly SERENITY)
     
  • Genetic Sucrase-Isomaltase Deficiency (GSID) Screening & Patient Survey Study (Protocol: GiHF-15-10)
     
  • An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications (Takeda EXPLORER) 
     
  • A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcohlic Steatohepatitis (REGENERATE) 
     
  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis (UNIFI)
     
  • A Phase 4 Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (AbbVie LEGACY)
     
  • A Multicentre, Open-label Study of Oral CP-690, 550 in subjects with Moderate to Severe Ulcerative Colitis (OCTAVE-Extention)
     
  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study 
    to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely Active Crohn’s Disease (IMUNIT)

Please visit  ClinicalTrials.gov  for detail information on clinical research studies listed.